nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CA9—kidney cancer	0.29	0.526	CbGaD
Methazolamide—CA2—kidney cancer	0.261	0.473	CbGaD
Methazolamide—CYP2D6—Temsirolimus—kidney cancer	0.0282	0.131	CbGbCtD
Methazolamide—CYP3A4—Everolimus—kidney cancer	0.0266	0.124	CbGbCtD
Methazolamide—CYP3A4—Temsirolimus—kidney cancer	0.0179	0.0835	CbGbCtD
Methazolamide—CYP2C9—Capecitabine—kidney cancer	0.0169	0.0787	CbGbCtD
Methazolamide—CYP2D6—Pazopanib—kidney cancer	0.0148	0.069	CbGbCtD
Methazolamide—CYP2C19—Sorafenib—kidney cancer	0.0113	0.0526	CbGbCtD
Methazolamide—CYP2C9—Paclitaxel—kidney cancer	0.0106	0.0493	CbGbCtD
Methazolamide—CYP2D6—Erlotinib—kidney cancer	0.0106	0.0492	CbGbCtD
Methazolamide—CYP3A4—Pazopanib—kidney cancer	0.00942	0.0439	CbGbCtD
Methazolamide—CYP2C9—Sorafenib—kidney cancer	0.0094	0.0438	CbGbCtD
Methazolamide—CYP2D6—Sorafenib—kidney cancer	0.0086	0.04	CbGbCtD
Methazolamide—CYP2D6—Vinblastine—kidney cancer	0.00849	0.0395	CbGbCtD
Methazolamide—CYP3A4—Erlotinib—kidney cancer	0.00672	0.0313	CbGbCtD
Methazolamide—CA2—collecting duct of renal tubule—kidney cancer	0.00647	0.171	CbGeAlD
Methazolamide—CYP3A4—Paclitaxel—kidney cancer	0.00616	0.0287	CbGbCtD
Methazolamide—CYP3A4—Sorafenib—kidney cancer	0.00547	0.0254	CbGbCtD
Methazolamide—CYP3A4—Vinblastine—kidney cancer	0.0054	0.0251	CbGbCtD
Methazolamide—CYP3A4—Vincristine—kidney cancer	0.00531	0.0247	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—kidney cancer	0.00522	0.0243	CbGbCtD
Methazolamide—CYP3A4—Sunitinib—kidney cancer	0.00443	0.0206	CbGbCtD
Methazolamide—CYP3A4—Doxorubicin—kidney cancer	0.00332	0.0154	CbGbCtD
Methazolamide—Acetazolamide—CA9—kidney cancer	0.00267	0.527	CrCbGaD
Methazolamide—CYP2C19—urine—kidney cancer	0.00252	0.0666	CbGeAlD
Methazolamide—Acetazolamide—CA2—kidney cancer	0.0024	0.473	CrCbGaD
Methazolamide—CYP2C9—urine—kidney cancer	0.00195	0.0516	CbGeAlD
Methazolamide—CYP2E1—urine—kidney cancer	0.00185	0.0489	CbGeAlD
Methazolamide—CA7—renal system—kidney cancer	0.00169	0.0448	CbGeAlD
Methazolamide—CA7—kidney—kidney cancer	0.00164	0.0433	CbGeAlD
Methazolamide—CYP3A4—urine—kidney cancer	0.00149	0.0394	CbGeAlD
Methazolamide—CYP2D6—urine—kidney cancer	0.00147	0.0387	CbGeAlD
Methazolamide—SLC22A6—nephron tubule—kidney cancer	0.00135	0.0357	CbGeAlD
Methazolamide—CA14—cardiac atrium—kidney cancer	0.00126	0.0334	CbGeAlD
Methazolamide—SLC22A6—cortex of kidney—kidney cancer	0.00116	0.0306	CbGeAlD
Methazolamide—CA12—renal system—kidney cancer	0.0011	0.0291	CbGeAlD
Methazolamide—CA12—kidney—kidney cancer	0.00106	0.0281	CbGeAlD
Methazolamide—CA5B—gonad—kidney cancer	0.000885	0.0234	CbGeAlD
Methazolamide—CA5B—cardiac atrium—kidney cancer	0.000884	0.0234	CbGeAlD
Methazolamide—CA1—renal system—kidney cancer	0.000872	0.023	CbGeAlD
Methazolamide—CA1—kidney—kidney cancer	0.000843	0.0223	CbGeAlD
Methazolamide—CA4—nephron tubule—kidney cancer	0.00075	0.0198	CbGeAlD
Methazolamide—CA4—renal system—kidney cancer	0.000681	0.018	CbGeAlD
Methazolamide—CA4—kidney—kidney cancer	0.000659	0.0174	CbGeAlD
Methazolamide—CA4—cortex of kidney—kidney cancer	0.000642	0.017	CbGeAlD
Methazolamide—CA2—nephron tubule—kidney cancer	0.000622	0.0164	CbGeAlD
Methazolamide—CA4—cardiac atrium—kidney cancer	0.00061	0.0161	CbGeAlD
Methazolamide—CA2—renal system—kidney cancer	0.000565	0.0149	CbGeAlD
Methazolamide—CA2—kidney—kidney cancer	0.000546	0.0144	CbGeAlD
Methazolamide—CA2—cortex of kidney—kidney cancer	0.000532	0.0141	CbGeAlD
Methazolamide—CA2—cardiac atrium—kidney cancer	0.000506	0.0134	CbGeAlD
Methazolamide—CYP2E1—nephron tubule—kidney cancer	0.000498	0.0132	CbGeAlD
Methazolamide—CYP2E1—renal system—kidney cancer	0.000453	0.012	CbGeAlD
Methazolamide—CYP2E1—kidney—kidney cancer	0.000438	0.0116	CbGeAlD
Methazolamide—CYP2E1—cortex of kidney—kidney cancer	0.000427	0.0113	CbGeAlD
Methazolamide—CYP3A4—renal system—kidney cancer	0.000365	0.00963	CbGeAlD
Methazolamide—CYP2D6—renal system—kidney cancer	0.000359	0.00948	CbGeAlD
Methazolamide—CYP3A4—kidney—kidney cancer	0.000352	0.00931	CbGeAlD
Methazolamide—CYP2D6—kidney—kidney cancer	0.000347	0.00916	CbGeAlD
Methazolamide—Hepatic failure—Capecitabine—kidney cancer	0.000325	0.00348	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Gemcitabine—kidney cancer	0.000324	0.00348	CcSEcCtD
Methazolamide—Dysgeusia—Sorafenib—kidney cancer	0.000324	0.00348	CcSEcCtD
Methazolamide—Haemolytic anaemia—Capecitabine—kidney cancer	0.000323	0.00347	CcSEcCtD
Methazolamide—Discomfort—Vinblastine—kidney cancer	0.000322	0.00346	CcSEcCtD
Methazolamide—Discomfort—Everolimus—kidney cancer	0.000321	0.00344	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Paclitaxel—kidney cancer	0.00032	0.00343	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—kidney cancer	0.00032	0.00343	CcSEcCtD
Methazolamide—Dysgeusia—Sunitinib—kidney cancer	0.000312	0.00335	CcSEcCtD
Methazolamide—Haematuria—Gemcitabine—kidney cancer	0.000312	0.00335	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—kidney cancer	0.00031	0.00333	CcSEcCtD
Methazolamide—Agranulocytosis—Gemcitabine—kidney cancer	0.000305	0.00328	CcSEcCtD
Methazolamide—Asthenia—Temsirolimus—kidney cancer	0.0003	0.00322	CcSEcCtD
Methazolamide—Anorexia—Vinblastine—kidney cancer	0.000298	0.0032	CcSEcCtD
Methazolamide—Anorexia—Everolimus—kidney cancer	0.000297	0.00318	CcSEcCtD
Methazolamide—Leukopenia—Sorafenib—kidney cancer	0.000296	0.00318	CcSEcCtD
Methazolamide—Pancytopenia—Paclitaxel—kidney cancer	0.000292	0.00313	CcSEcCtD
Methazolamide—Diarrhoea—Temsirolimus—kidney cancer	0.000286	0.00307	CcSEcCtD
Methazolamide—Anorexia—Erlotinib—kidney cancer	0.000286	0.00307	CcSEcCtD
Methazolamide—Leukopenia—Sunitinib—kidney cancer	0.000285	0.00306	CcSEcCtD
Methazolamide—Asthenia—Pazopanib—kidney cancer	0.000283	0.00304	CcSEcCtD
Methazolamide—Paraesthesia—Vinblastine—kidney cancer	0.000281	0.00301	CcSEcCtD
Methazolamide—Photosensitivity reaction—Paclitaxel—kidney cancer	0.00028	0.00301	CcSEcCtD
Methazolamide—Ill-defined disorder—Dactinomycin—kidney cancer	0.00028	0.003	CcSEcCtD
Methazolamide—Paraesthesia—Everolimus—kidney cancer	0.00028	0.003	CcSEcCtD
Methazolamide—Erythema multiforme—Gemcitabine—kidney cancer	0.000278	0.00298	CcSEcCtD
Methazolamide—Somnolence—Everolimus—kidney cancer	0.000277	0.00297	CcSEcCtD
Methazolamide—Convulsion—Sunitinib—kidney cancer	0.000276	0.00296	CcSEcCtD
Methazolamide—Dyspepsia—Everolimus—kidney cancer	0.000274	0.00294	CcSEcCtD
Methazolamide—Malaise—Dactinomycin—kidney cancer	0.000272	0.00292	CcSEcCtD
Methazolamide—Decreased appetite—Vinblastine—kidney cancer	0.000272	0.00292	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Paclitaxel—kidney cancer	0.000272	0.00291	CcSEcCtD
Methazolamide—Decreased appetite—Everolimus—kidney cancer	0.000271	0.0029	CcSEcCtD
Methazolamide—Anaphylactic shock—Sorafenib—kidney cancer	0.00027	0.0029	CcSEcCtD
Methazolamide—Leukopenia—Dactinomycin—kidney cancer	0.00027	0.0029	CcSEcCtD
Methazolamide—Diarrhoea—Pazopanib—kidney cancer	0.00027	0.0029	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Everolimus—kidney cancer	0.000269	0.00288	CcSEcCtD
Methazolamide—Fatigue—Everolimus—kidney cancer	0.000268	0.00288	CcSEcCtD
Methazolamide—Vomiting—Temsirolimus—kidney cancer	0.000266	0.00286	CcSEcCtD
Methazolamide—Dyspepsia—Erlotinib—kidney cancer	0.000264	0.00284	CcSEcCtD
Methazolamide—Rash—Temsirolimus—kidney cancer	0.000264	0.00283	CcSEcCtD
Methazolamide—Dermatitis—Temsirolimus—kidney cancer	0.000264	0.00283	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.000263	0.00282	CcSEcCtD
Methazolamide—Headache—Temsirolimus—kidney cancer	0.000262	0.00281	CcSEcCtD
Methazolamide—Haematuria—Paclitaxel—kidney cancer	0.000261	0.0028	CcSEcCtD
Methazolamide—Decreased appetite—Erlotinib—kidney cancer	0.000261	0.0028	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000259	0.00278	CcSEcCtD
Methazolamide—Fatigue—Erlotinib—kidney cancer	0.000259	0.00278	CcSEcCtD
Methazolamide—Anorexia—Sorafenib—kidney cancer	0.000258	0.00276	CcSEcCtD
Methazolamide—Feeling abnormal—Vinblastine—kidney cancer	0.000258	0.00276	CcSEcCtD
Methazolamide—Feeling abnormal—Everolimus—kidney cancer	0.000257	0.00275	CcSEcCtD
Methazolamide—Discomfort—Dactinomycin—kidney cancer	0.000254	0.00272	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—kidney cancer	0.000253	0.00272	CcSEcCtD
Methazolamide—Vomiting—Pazopanib—kidney cancer	0.000251	0.00269	CcSEcCtD
Methazolamide—Rash—Pazopanib—kidney cancer	0.000249	0.00267	CcSEcCtD
Methazolamide—Nausea—Temsirolimus—kidney cancer	0.000249	0.00267	CcSEcCtD
Methazolamide—Dermatitis—Pazopanib—kidney cancer	0.000248	0.00267	CcSEcCtD
Methazolamide—Anorexia—Sunitinib—kidney cancer	0.000248	0.00266	CcSEcCtD
Methazolamide—Headache—Pazopanib—kidney cancer	0.000247	0.00265	CcSEcCtD
Methazolamide—Body temperature increased—Everolimus—kidney cancer	0.000246	0.00264	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—kidney cancer	0.000243	0.00261	CcSEcCtD
Methazolamide—Vertigo—Vincristine—kidney cancer	0.000242	0.0026	CcSEcCtD
Methazolamide—Leukopenia—Vincristine—kidney cancer	0.000241	0.00259	CcSEcCtD
Methazolamide—Pancytopenia—Capecitabine—kidney cancer	0.000239	0.00257	CcSEcCtD
Methazolamide—Dyspepsia—Sorafenib—kidney cancer	0.000238	0.00255	CcSEcCtD
Methazolamide—Body temperature increased—Erlotinib—kidney cancer	0.000237	0.00255	CcSEcCtD
Methazolamide—Ill-defined disorder—Gemcitabine—kidney cancer	0.000237	0.00255	CcSEcCtD
Methazolamide—Decreased appetite—Sorafenib—kidney cancer	0.000235	0.00252	CcSEcCtD
Methazolamide—Anorexia—Dactinomycin—kidney cancer	0.000235	0.00252	CcSEcCtD
Methazolamide—Nausea—Pazopanib—kidney cancer	0.000234	0.00251	CcSEcCtD
Methazolamide—Paraesthesia—Sunitinib—kidney cancer	0.000233	0.00251	CcSEcCtD
Methazolamide—Convulsion—Vincristine—kidney cancer	0.000233	0.00251	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000233	0.0025	CcSEcCtD
Methazolamide—Fatigue—Sorafenib—kidney cancer	0.000233	0.0025	CcSEcCtD
Methazolamide—Erythema multiforme—Paclitaxel—kidney cancer	0.000232	0.0025	CcSEcCtD
Methazolamide—Malaise—Gemcitabine—kidney cancer	0.000231	0.00247	CcSEcCtD
Methazolamide—Photosensitivity reaction—Capecitabine—kidney cancer	0.00023	0.00247	CcSEcCtD
Methazolamide—Tinnitus—Paclitaxel—kidney cancer	0.000229	0.00246	CcSEcCtD
Methazolamide—Dyspepsia—Sunitinib—kidney cancer	0.000229	0.00246	CcSEcCtD
Methazolamide—Leukopenia—Gemcitabine—kidney cancer	0.000229	0.00246	CcSEcCtD
Methazolamide—Decreased appetite—Sunitinib—kidney cancer	0.000226	0.00243	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000224	0.00241	CcSEcCtD
Methazolamide—Asthenia—Vinblastine—kidney cancer	0.000224	0.00241	CcSEcCtD
Methazolamide—Fatigue—Sunitinib—kidney cancer	0.000224	0.00241	CcSEcCtD
Methazolamide—Asthenia—Everolimus—kidney cancer	0.000223	0.0024	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000223	0.00239	CcSEcCtD
Methazolamide—Anaphylactic shock—Vincristine—kidney cancer	0.00022	0.00236	CcSEcCtD
Methazolamide—Asthenia—Erlotinib—kidney cancer	0.000216	0.00231	CcSEcCtD
Methazolamide—Discomfort—Gemcitabine—kidney cancer	0.000215	0.00231	CcSEcCtD
Methazolamide—Urticaria—Sorafenib—kidney cancer	0.000215	0.0023	CcSEcCtD
Methazolamide—Haematuria—Capecitabine—kidney cancer	0.000214	0.0023	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—kidney cancer	0.000214	0.0023	CcSEcCtD
Methazolamide—Decreased appetite—Dactinomycin—kidney cancer	0.000214	0.0023	CcSEcCtD
Methazolamide—Diarrhoea—Vinblastine—kidney cancer	0.000214	0.00229	CcSEcCtD
Methazolamide—Body temperature increased—Sorafenib—kidney cancer	0.000214	0.00229	CcSEcCtD
Methazolamide—Diarrhoea—Everolimus—kidney cancer	0.000213	0.00229	CcSEcCtD
Methazolamide—Fatigue—Dactinomycin—kidney cancer	0.000212	0.00228	CcSEcCtD
Methazolamide—Agranulocytosis—Capecitabine—kidney cancer	0.00021	0.00225	CcSEcCtD
Methazolamide—Anorexia—Vincristine—kidney cancer	0.00021	0.00225	CcSEcCtD
Methazolamide—Dysgeusia—Paclitaxel—kidney cancer	0.00021	0.00225	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—kidney cancer	0.000209	0.00225	CcSEcCtD
Methazolamide—Anaphylactic shock—Gemcitabine—kidney cancer	0.000209	0.00224	CcSEcCtD
Methazolamide—Body temperature increased—Sunitinib—kidney cancer	0.000206	0.00221	CcSEcCtD
Methazolamide—Diarrhoea—Erlotinib—kidney cancer	0.000206	0.00221	CcSEcCtD
Methazolamide—Feeling abnormal—Dactinomycin—kidney cancer	0.000203	0.00218	CcSEcCtD
Methazolamide—Anorexia—Gemcitabine—kidney cancer	0.000199	0.00213	CcSEcCtD
Methazolamide—Vomiting—Vinblastine—kidney cancer	0.000199	0.00213	CcSEcCtD
Methazolamide—Ill-defined disorder—Paclitaxel—kidney cancer	0.000199	0.00213	CcSEcCtD
Methazolamide—Vomiting—Everolimus—kidney cancer	0.000198	0.00212	CcSEcCtD
Methazolamide—Paraesthesia—Vincristine—kidney cancer	0.000197	0.00212	CcSEcCtD
Methazolamide—Rash—Everolimus—kidney cancer	0.000196	0.00211	CcSEcCtD
Methazolamide—Dermatitis—Everolimus—kidney cancer	0.000196	0.0021	CcSEcCtD
Methazolamide—Headache—Vinblastine—kidney cancer	0.000196	0.0021	CcSEcCtD
Methazolamide—Headache—Everolimus—kidney cancer	0.000195	0.00209	CcSEcCtD
Methazolamide—Body temperature increased—Dactinomycin—kidney cancer	0.000195	0.00209	CcSEcCtD
Methazolamide—Asthenia—Sorafenib—kidney cancer	0.000194	0.00208	CcSEcCtD
Methazolamide—Malaise—Paclitaxel—kidney cancer	0.000193	0.00207	CcSEcCtD
Methazolamide—Vertigo—Paclitaxel—kidney cancer	0.000192	0.00206	CcSEcCtD
Methazolamide—Leukopenia—Paclitaxel—kidney cancer	0.000192	0.00206	CcSEcCtD
Methazolamide—Decreased appetite—Vincristine—kidney cancer	0.000191	0.00205	CcSEcCtD
Methazolamide—Vomiting—Erlotinib—kidney cancer	0.000191	0.00205	CcSEcCtD
Methazolamide—Erythema multiforme—Capecitabine—kidney cancer	0.000191	0.00205	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Vincristine—kidney cancer	0.00019	0.00204	CcSEcCtD
Methazolamide—Fatigue—Vincristine—kidney cancer	0.00019	0.00204	CcSEcCtD
Methazolamide—Rash—Erlotinib—kidney cancer	0.000189	0.00203	CcSEcCtD
Methazolamide—Dermatitis—Erlotinib—kidney cancer	0.000189	0.00203	CcSEcCtD
Methazolamide—Headache—Erlotinib—kidney cancer	0.000188	0.00202	CcSEcCtD
Methazolamide—Tinnitus—Capecitabine—kidney cancer	0.000188	0.00202	CcSEcCtD
Methazolamide—Paraesthesia—Gemcitabine—kidney cancer	0.000187	0.00201	CcSEcCtD
Methazolamide—Asthenia—Sunitinib—kidney cancer	0.000187	0.002	CcSEcCtD
Methazolamide—Nausea—Vinblastine—kidney cancer	0.000186	0.00199	CcSEcCtD
Methazolamide—Somnolence—Gemcitabine—kidney cancer	0.000185	0.00199	CcSEcCtD
Methazolamide—Convulsion—Paclitaxel—kidney cancer	0.000185	0.00199	CcSEcCtD
Methazolamide—Nausea—Everolimus—kidney cancer	0.000185	0.00198	CcSEcCtD
Methazolamide—Diarrhoea—Sorafenib—kidney cancer	0.000185	0.00198	CcSEcCtD
Methazolamide—Decreased appetite—Gemcitabine—kidney cancer	0.000181	0.00195	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00018	0.00193	CcSEcCtD
Methazolamide—Discomfort—Paclitaxel—kidney cancer	0.00018	0.00193	CcSEcCtD
Methazolamide—Fatigue—Gemcitabine—kidney cancer	0.00018	0.00193	CcSEcCtD
Methazolamide—Nausea—Erlotinib—kidney cancer	0.000178	0.00191	CcSEcCtD
Methazolamide—Diarrhoea—Sunitinib—kidney cancer	0.000178	0.00191	CcSEcCtD
Methazolamide—Asthenia—Dactinomycin—kidney cancer	0.000177	0.0019	CcSEcCtD
Methazolamide—Confusional state—Paclitaxel—kidney cancer	0.000176	0.00189	CcSEcCtD
Methazolamide—Anaphylactic shock—Paclitaxel—kidney cancer	0.000175	0.00187	CcSEcCtD
Methazolamide—Body temperature increased—Vincristine—kidney cancer	0.000174	0.00187	CcSEcCtD
Methazolamide—Dysgeusia—Capecitabine—kidney cancer	0.000172	0.00185	CcSEcCtD
Methazolamide—Feeling abnormal—Gemcitabine—kidney cancer	0.000172	0.00185	CcSEcCtD
Methazolamide—Vomiting—Sorafenib—kidney cancer	0.000172	0.00184	CcSEcCtD
Methazolamide—Rash—Sorafenib—kidney cancer	0.00017	0.00183	CcSEcCtD
Methazolamide—Dermatitis—Sorafenib—kidney cancer	0.00017	0.00183	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000169	0.00182	CcSEcCtD
Methazolamide—Headache—Sorafenib—kidney cancer	0.000169	0.00182	CcSEcCtD
Methazolamide—Diarrhoea—Dactinomycin—kidney cancer	0.000168	0.00181	CcSEcCtD
Methazolamide—Anorexia—Paclitaxel—kidney cancer	0.000167	0.00179	CcSEcCtD
Methazolamide—Vomiting—Sunitinib—kidney cancer	0.000165	0.00177	CcSEcCtD
Methazolamide—Body temperature increased—Gemcitabine—kidney cancer	0.000165	0.00177	CcSEcCtD
Methazolamide—Rash—Sunitinib—kidney cancer	0.000164	0.00176	CcSEcCtD
Methazolamide—Dermatitis—Sunitinib—kidney cancer	0.000164	0.00176	CcSEcCtD
Methazolamide—Ill-defined disorder—Capecitabine—kidney cancer	0.000163	0.00175	CcSEcCtD
Methazolamide—Headache—Sunitinib—kidney cancer	0.000163	0.00175	CcSEcCtD
Methazolamide—Nausea—Sorafenib—kidney cancer	0.000161	0.00172	CcSEcCtD
Methazolamide—Malaise—Capecitabine—kidney cancer	0.000158	0.0017	CcSEcCtD
Methazolamide—Vertigo—Capecitabine—kidney cancer	0.000158	0.00169	CcSEcCtD
Methazolamide—Asthenia—Vincristine—kidney cancer	0.000158	0.00169	CcSEcCtD
Methazolamide—Leukopenia—Capecitabine—kidney cancer	0.000157	0.00169	CcSEcCtD
Methazolamide—Paraesthesia—Paclitaxel—kidney cancer	0.000157	0.00168	CcSEcCtD
Methazolamide—Vomiting—Dactinomycin—kidney cancer	0.000157	0.00168	CcSEcCtD
Methazolamide—Somnolence—Paclitaxel—kidney cancer	0.000155	0.00167	CcSEcCtD
Methazolamide—Rash—Dactinomycin—kidney cancer	0.000155	0.00167	CcSEcCtD
Methazolamide—Nausea—Sunitinib—kidney cancer	0.000154	0.00166	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—kidney cancer	0.000154	0.00166	CcSEcCtD
Methazolamide—Dyspepsia—Paclitaxel—kidney cancer	0.000154	0.00165	CcSEcCtD
Methazolamide—Decreased appetite—Paclitaxel—kidney cancer	0.000152	0.00163	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000151	0.00162	CcSEcCtD
Methazolamide—Fatigue—Paclitaxel—kidney cancer	0.000151	0.00162	CcSEcCtD
Methazolamide—Diarrhoea—Vincristine—kidney cancer	0.00015	0.00162	CcSEcCtD
Methazolamide—Asthenia—Gemcitabine—kidney cancer	0.00015	0.00161	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000148	0.00159	CcSEcCtD
Methazolamide—Discomfort—Capecitabine—kidney cancer	0.000148	0.00159	CcSEcCtD
Methazolamide—Nausea—Dactinomycin—kidney cancer	0.000146	0.00157	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—kidney cancer	0.000145	0.00155	CcSEcCtD
Methazolamide—Confusional state—Capecitabine—kidney cancer	0.000145	0.00155	CcSEcCtD
Methazolamide—Feeling abnormal—Paclitaxel—kidney cancer	0.000144	0.00154	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000144	0.00154	CcSEcCtD
Methazolamide—Diarrhoea—Gemcitabine—kidney cancer	0.000143	0.00153	CcSEcCtD
Methazolamide—Vomiting—Vincristine—kidney cancer	0.00014	0.0015	CcSEcCtD
Methazolamide—Urticaria—Paclitaxel—kidney cancer	0.000139	0.00149	CcSEcCtD
Methazolamide—Rash—Vincristine—kidney cancer	0.000139	0.00149	CcSEcCtD
Methazolamide—Dermatitis—Vincristine—kidney cancer	0.000139	0.00149	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—kidney cancer	0.000138	0.00148	CcSEcCtD
Methazolamide—Body temperature increased—Paclitaxel—kidney cancer	0.000138	0.00148	CcSEcCtD
Methazolamide—Headache—Vincristine—kidney cancer	0.000138	0.00148	CcSEcCtD
Methazolamide—Anorexia—Capecitabine—kidney cancer	0.000137	0.00147	CcSEcCtD
Methazolamide—Agranulocytosis—Doxorubicin—kidney cancer	0.000135	0.00145	CcSEcCtD
Methazolamide—Vomiting—Gemcitabine—kidney cancer	0.000133	0.00142	CcSEcCtD
Methazolamide—Rash—Gemcitabine—kidney cancer	0.000132	0.00141	CcSEcCtD
Methazolamide—Dermatitis—Gemcitabine—kidney cancer	0.000131	0.00141	CcSEcCtD
Methazolamide—Headache—Gemcitabine—kidney cancer	0.000131	0.0014	CcSEcCtD
Methazolamide—Nausea—Vincristine—kidney cancer	0.000131	0.0014	CcSEcCtD
Methazolamide—Paraesthesia—Capecitabine—kidney cancer	0.000129	0.00138	CcSEcCtD
Methazolamide—Dyspepsia—Capecitabine—kidney cancer	0.000126	0.00135	CcSEcCtD
Methazolamide—Asthenia—Paclitaxel—kidney cancer	0.000125	0.00135	CcSEcCtD
Methazolamide—Decreased appetite—Capecitabine—kidney cancer	0.000125	0.00134	CcSEcCtD
Methazolamide—Nausea—Gemcitabine—kidney cancer	0.000124	0.00133	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000124	0.00133	CcSEcCtD
Methazolamide—Fatigue—Capecitabine—kidney cancer	0.000124	0.00133	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—kidney cancer	0.000123	0.00132	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—kidney cancer	0.000121	0.0013	CcSEcCtD
Methazolamide—Diarrhoea—Paclitaxel—kidney cancer	0.00012	0.00128	CcSEcCtD
Methazolamide—Feeling abnormal—Capecitabine—kidney cancer	0.000118	0.00127	CcSEcCtD
Methazolamide—Urticaria—Capecitabine—kidney cancer	0.000114	0.00122	CcSEcCtD
Methazolamide—Body temperature increased—Capecitabine—kidney cancer	0.000113	0.00122	CcSEcCtD
Methazolamide—Vomiting—Paclitaxel—kidney cancer	0.000111	0.00119	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—kidney cancer	0.000111	0.00119	CcSEcCtD
Methazolamide—Rash—Paclitaxel—kidney cancer	0.00011	0.00118	CcSEcCtD
Methazolamide—Dermatitis—Paclitaxel—kidney cancer	0.00011	0.00118	CcSEcCtD
Methazolamide—Headache—Paclitaxel—kidney cancer	0.000109	0.00117	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—kidney cancer	0.000105	0.00113	CcSEcCtD
Methazolamide—Nausea—Paclitaxel—kidney cancer	0.000104	0.00111	CcSEcCtD
Methazolamide—Asthenia—Capecitabine—kidney cancer	0.000103	0.0011	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—kidney cancer	0.000102	0.0011	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—kidney cancer	0.000102	0.00109	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—kidney cancer	0.000101	0.00109	CcSEcCtD
Methazolamide—Convulsion—Doxorubicin—kidney cancer	9.81e-05	0.00105	CcSEcCtD
Methazolamide—Diarrhoea—Capecitabine—kidney cancer	9.81e-05	0.00105	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—kidney cancer	9.52e-05	0.00102	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—kidney cancer	9.32e-05	0.001	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—kidney cancer	9.24e-05	0.000992	CcSEcCtD
Methazolamide—Vomiting—Capecitabine—kidney cancer	9.11e-05	0.000978	CcSEcCtD
Methazolamide—Rash—Capecitabine—kidney cancer	9.04e-05	0.00097	CcSEcCtD
Methazolamide—Dermatitis—Capecitabine—kidney cancer	9.03e-05	0.000969	CcSEcCtD
Methazolamide—Headache—Capecitabine—kidney cancer	8.98e-05	0.000964	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—kidney cancer	8.81e-05	0.000945	CcSEcCtD
Methazolamide—Nausea—Capecitabine—kidney cancer	8.51e-05	0.000914	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—kidney cancer	8.3e-05	0.000891	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—kidney cancer	8.21e-05	0.000882	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—kidney cancer	8.13e-05	0.000873	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—kidney cancer	8.03e-05	0.000862	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.98e-05	0.000856	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—kidney cancer	7.97e-05	0.000855	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—kidney cancer	7.61e-05	0.000817	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—kidney cancer	7.34e-05	0.000788	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—kidney cancer	7.3e-05	0.000784	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—kidney cancer	6.63e-05	0.000712	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—kidney cancer	6.32e-05	0.000679	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—kidney cancer	5.88e-05	0.000631	CcSEcCtD
Methazolamide—Rash—Doxorubicin—kidney cancer	5.83e-05	0.000625	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—kidney cancer	5.82e-05	0.000625	CcSEcCtD
Methazolamide—Headache—Doxorubicin—kidney cancer	5.79e-05	0.000621	CcSEcCtD
Methazolamide—Nausea—Doxorubicin—kidney cancer	5.49e-05	0.000589	CcSEcCtD
Methazolamide—CA4—Metabolism—ABCB1—kidney cancer	1.85e-05	0.000188	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—POMC—kidney cancer	1.84e-05	0.000187	CbGpPWpGaD
Methazolamide—CA6—Metabolism—POMC—kidney cancer	1.84e-05	0.000187	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ACY1—kidney cancer	1.82e-05	0.000185	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ACY1—kidney cancer	1.8e-05	0.000183	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTP1—kidney cancer	1.79e-05	0.000182	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GSTM1—kidney cancer	1.79e-05	0.000182	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PPAT—kidney cancer	1.78e-05	0.000181	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GLIPR1—kidney cancer	1.78e-05	0.000181	CbGpPWpGaD
Methazolamide—CA2—Metabolism—ABCB1—kidney cancer	1.77e-05	0.00018	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GSTM1—kidney cancer	1.72e-05	0.000175	CbGpPWpGaD
Methazolamide—CA7—Metabolism—POMC—kidney cancer	1.71e-05	0.000174	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—POMC—kidney cancer	1.71e-05	0.000174	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP1A1—kidney cancer	1.7e-05	0.000173	CbGpPWpGaD
Methazolamide—CA1—Metabolism—ABCB1—kidney cancer	1.7e-05	0.000173	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	1.68e-05	0.000172	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PDHB—kidney cancer	1.68e-05	0.000171	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—POMC—kidney cancer	1.67e-05	0.00017	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—FH—kidney cancer	1.65e-05	0.000168	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—APRT—kidney cancer	1.65e-05	0.000168	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTM1—kidney cancer	1.65e-05	0.000168	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP1A1—kidney cancer	1.63e-05	0.000166	CbGpPWpGaD
Methazolamide—CA12—Metabolism—POMC—kidney cancer	1.59e-05	0.000162	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CCBL1—kidney cancer	1.58e-05	0.000161	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTP1—kidney cancer	1.58e-05	0.00016	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP1A1—kidney cancer	1.56e-05	0.000159	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GPC3—kidney cancer	1.55e-05	0.000158	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTP1—kidney cancer	1.55e-05	0.000158	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PDHB—kidney cancer	1.55e-05	0.000157	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—POMC—kidney cancer	1.54e-05	0.000157	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	1.54e-05	0.000156	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PDHB—kidney cancer	1.53e-05	0.000156	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	1.53e-05	0.000156	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—POMC—kidney cancer	1.53e-05	0.000155	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CA2—kidney cancer	1.51e-05	0.000154	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTGS2—kidney cancer	1.5e-05	0.000153	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ABCB1—kidney cancer	1.49e-05	0.000152	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ALAD—kidney cancer	1.47e-05	0.00015	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTGS2—kidney cancer	1.46e-05	0.000149	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTGS2—kidney cancer	1.46e-05	0.000149	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CCBL1—kidney cancer	1.45e-05	0.000148	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTM1—kidney cancer	1.45e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CCBL1—kidney cancer	1.44e-05	0.000147	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ST3GAL2—kidney cancer	1.44e-05	0.000146	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	1.43e-05	0.000145	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTM1—kidney cancer	1.42e-05	0.000145	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	1.41e-05	0.000143	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ALDH1A1—kidney cancer	1.4e-05	0.000143	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP1A1—kidney cancer	1.37e-05	0.00014	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GLIPR1—kidney cancer	1.37e-05	0.000139	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PPAT—kidney cancer	1.37e-05	0.000139	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTGS2—kidney cancer	1.37e-05	0.000139	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTGS2—kidney cancer	1.37e-05	0.000139	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.35e-05	0.000138	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	1.35e-05	0.000137	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PGK1—kidney cancer	1.35e-05	0.000137	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SLC5A3—kidney cancer	1.35e-05	0.000137	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.34e-05	0.000136	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.33e-05	0.000136	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—LDHB—kidney cancer	1.32e-05	0.000134	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTEN—kidney cancer	1.31e-05	0.000133	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	1.3e-05	0.000133	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTEN—kidney cancer	1.28e-05	0.00013	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTEN—kidney cancer	1.28e-05	0.00013	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—APRT—kidney cancer	1.27e-05	0.00013	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—FH—kidney cancer	1.27e-05	0.00013	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTGS2—kidney cancer	1.27e-05	0.000129	CbGpPWpGaD
Methazolamide—CA4—Metabolism—POMC—kidney cancer	1.27e-05	0.000129	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GLIPR1—kidney cancer	1.26e-05	0.000128	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PPAT—kidney cancer	1.26e-05	0.000128	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GLIPR1—kidney cancer	1.25e-05	0.000127	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PPAT—kidney cancer	1.25e-05	0.000127	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.24e-05	0.000127	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	1.23e-05	0.000126	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	1.22e-05	0.000124	CbGpPWpGaD
Methazolamide—CA2—Metabolism—POMC—kidney cancer	1.21e-05	0.000124	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GPC3—kidney cancer	1.2e-05	0.000122	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTEN—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTEN—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ACY1—kidney cancer	1.19e-05	0.000121	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—APRT—kidney cancer	1.17e-05	0.000119	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—FH—kidney cancer	1.17e-05	0.000119	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CA2—kidney cancer	1.16e-05	0.000119	CbGpPWpGaD
Methazolamide—CA1—Metabolism—POMC—kidney cancer	1.16e-05	0.000118	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—APRT—kidney cancer	1.16e-05	0.000118	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—FH—kidney cancer	1.16e-05	0.000118	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CA9—kidney cancer	1.14e-05	0.000116	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALAD—kidney cancer	1.13e-05	0.000116	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.13e-05	0.000115	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ST3GAL2—kidney cancer	1.11e-05	0.000113	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTEN—kidney cancer	1.1e-05	0.000112	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GPC3—kidney cancer	1.1e-05	0.000112	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GPC3—kidney cancer	1.09e-05	0.000111	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ALDH1A1—kidney cancer	1.08e-05	0.00011	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	1.08e-05	0.00011	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CA2—kidney cancer	1.07e-05	0.000109	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CA2—kidney cancer	1.06e-05	0.000108	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALAD—kidney cancer	1.04e-05	0.000106	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SLC5A3—kidney cancer	1.04e-05	0.000106	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PGK1—kidney cancer	1.04e-05	0.000106	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALAD—kidney cancer	1.03e-05	0.000105	CbGpPWpGaD
Methazolamide—CA9—Metabolism—POMC—kidney cancer	1.02e-05	0.000104	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.02e-05	0.000104	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—LDHB—kidney cancer	1.02e-05	0.000104	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PDHB—kidney cancer	1.01e-05	0.000103	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.01e-05	0.000103	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—kidney cancer	1.01e-05	0.000103	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—POMC—kidney cancer	1.01e-05	0.000103	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ALDH1A1—kidney cancer	9.96e-06	0.000101	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	9.87e-06	0.0001	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CRABP1—kidney cancer	9.73e-06	9.9e-05	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—kidney cancer	9.68e-06	9.86e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PGK1—kidney cancer	9.55e-06	9.72e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SLC5A3—kidney cancer	9.55e-06	9.72e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CCBL1—kidney cancer	9.5e-06	9.67e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PGK1—kidney cancer	9.46e-06	9.63e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SLC5A3—kidney cancer	9.46e-06	9.63e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—LDHB—kidney cancer	9.36e-06	9.53e-05	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—kidney cancer	9.28e-06	9.45e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—LDHB—kidney cancer	9.28e-06	9.45e-05	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PIK3CA—kidney cancer	9.24e-06	9.41e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ITPR2—kidney cancer	9.04e-06	9.2e-05	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PIK3CA—kidney cancer	9.01e-06	9.17e-05	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PIK3CA—kidney cancer	9.01e-06	9.17e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CA9—kidney cancer	8.83e-06	8.98e-05	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTEN—kidney cancer	8.81e-06	8.96e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.63e-06	8.78e-05	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTEN—kidney cancer	8.44e-06	8.59e-05	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PIK3CA—kidney cancer	8.41e-06	8.56e-05	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PIK3CA—kidney cancer	8.41e-06	8.56e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTT1—kidney cancer	8.25e-06	8.39e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ACHE—kidney cancer	8.25e-06	8.39e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GLIPR1—kidney cancer	8.24e-06	8.38e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PPAT—kidney cancer	8.24e-06	8.38e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—kidney cancer	8.16e-06	8.31e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CA9—kidney cancer	8.12e-06	8.26e-05	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTEN—kidney cancer	8.09e-06	8.24e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CA9—kidney cancer	8.05e-06	8.19e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	7.86e-06	8.01e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SCARB1—kidney cancer	7.81e-06	7.95e-05	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PIK3CA—kidney cancer	7.79e-06	7.93e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS1—kidney cancer	7.73e-06	7.86e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—APRT—kidney cancer	7.66e-06	7.79e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—FH—kidney cancer	7.66e-06	7.79e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PSMD7—kidney cancer	7.58e-06	7.71e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CRABP1—kidney cancer	7.5e-06	7.64e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GPC3—kidney cancer	7.2e-06	7.33e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—BCHE—kidney cancer	7.18e-06	7.31e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTEN—kidney cancer	7.12e-06	7.24e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SLC5A5—kidney cancer	7.1e-06	7.22e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CA2—kidney cancer	7e-06	7.13e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ITPR2—kidney cancer	6.98e-06	7.1e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CRABP1—kidney cancer	6.9e-06	7.03e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—SLC2A1—kidney cancer	6.85e-06	6.98e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CRABP1—kidney cancer	6.84e-06	6.96e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALAD—kidney cancer	6.82e-06	6.95e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.66e-06	6.78e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.51e-06	6.63e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.43e-06	6.55e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ITPR2—kidney cancer	6.42e-06	6.53e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ACHE—kidney cancer	6.36e-06	6.48e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTT1—kidney cancer	6.36e-06	6.48e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ITPR2—kidney cancer	6.36e-06	6.47e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.24e-06	6.35e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PGK1—kidney cancer	6.24e-06	6.35e-05	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PIK3CA—kidney cancer	6.21e-06	6.32e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—LDHB—kidney cancer	6.12e-06	6.23e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SCARB1—kidney cancer	6.02e-06	6.13e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS1—kidney cancer	5.96e-06	6.07e-05	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PIK3CA—kidney cancer	5.96e-06	6.06e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.86e-06	5.97e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTT1—kidney cancer	5.85e-06	5.96e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ACHE—kidney cancer	5.85e-06	5.96e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PSMD7—kidney cancer	5.85e-06	5.95e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ACHE—kidney cancer	5.8e-06	5.9e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTT1—kidney cancer	5.8e-06	5.9e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTP1—kidney cancer	5.72e-06	5.82e-05	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PIK3CA—kidney cancer	5.71e-06	5.81e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—BCHE—kidney cancer	5.54e-06	5.64e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SCARB1—kidney cancer	5.54e-06	5.64e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SCARB1—kidney cancer	5.49e-06	5.59e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS1—kidney cancer	5.48e-06	5.58e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SLC5A5—kidney cancer	5.47e-06	5.57e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS1—kidney cancer	5.44e-06	5.53e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ABCB1—kidney cancer	5.41e-06	5.51e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PSMD7—kidney cancer	5.38e-06	5.47e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PSMD7—kidney cancer	5.33e-06	5.43e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CA9—kidney cancer	5.31e-06	5.4e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—SLC2A1—kidney cancer	5.29e-06	5.38e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTM1—kidney cancer	5.25e-06	5.35e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.13e-06	5.22e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—BCHE—kidney cancer	5.1e-06	5.19e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—BCHE—kidney cancer	5.05e-06	5.14e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.03e-06	5.13e-05	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PIK3CA—kidney cancer	5.02e-06	5.11e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SLC5A5—kidney cancer	4.99e-06	5.08e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP1A1—kidney cancer	4.98e-06	5.07e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.86e-06	4.95e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.82e-06	4.91e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.68e-06	4.76e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CRABP1—kidney cancer	4.51e-06	4.59e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.47e-06	4.55e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTP1—kidney cancer	4.41e-06	4.49e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ITPR2—kidney cancer	4.2e-06	4.27e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ABCB1—kidney cancer	4.17e-06	4.25e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.08e-06	4.15e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTP1—kidney cancer	4.06e-06	4.13e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTM1—kidney cancer	4.05e-06	4.12e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTP1—kidney cancer	4.02e-06	4.09e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP1A1—kidney cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ABCB1—kidney cancer	3.84e-06	3.91e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ACHE—kidney cancer	3.83e-06	3.89e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTT1—kidney cancer	3.83e-06	3.89e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ABCB1—kidney cancer	3.81e-06	3.87e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTM1—kidney cancer	3.73e-06	3.79e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—POMC—kidney cancer	3.71e-06	3.78e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTM1—kidney cancer	3.69e-06	3.76e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SCARB1—kidney cancer	3.62e-06	3.69e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS1—kidney cancer	3.58e-06	3.65e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.53e-06	3.6e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PSMD7—kidney cancer	3.52e-06	3.58e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.5e-06	3.57e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—BCHE—kidney cancer	3.33e-06	3.39e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.29e-06	3.35e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.18e-06	3.24e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.16e-06	3.21e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—kidney cancer	2.96e-06	3.01e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.88e-06	2.93e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—POMC—kidney cancer	2.86e-06	2.92e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTP1—kidney cancer	2.65e-06	2.7e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—POMC—kidney cancer	2.63e-06	2.68e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—POMC—kidney cancer	2.61e-06	2.66e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTEN—kidney cancer	2.58e-06	2.63e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ABCB1—kidney cancer	2.51e-06	2.55e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTM1—kidney cancer	2.44e-06	2.48e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.31e-06	2.35e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—kidney cancer	2.28e-06	2.33e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—kidney cancer	2.1e-06	2.14e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—kidney cancer	2.08e-06	2.12e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTEN—kidney cancer	1.99e-06	2.03e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTEN—kidney cancer	1.83e-06	1.87e-05	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PIK3CA—kidney cancer	1.82e-06	1.85e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTEN—kidney cancer	1.82e-06	1.85e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—POMC—kidney cancer	1.72e-06	1.75e-05	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.41e-06	1.43e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—kidney cancer	1.37e-06	1.4e-05	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.29e-06	1.32e-05	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.28e-06	1.3e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTEN—kidney cancer	1.2e-06	1.22e-05	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.45e-07	8.6e-06	CbGpPWpGaD
